The discovery of the involvement of LRRK2 in PD and its ability to modulate various pro-inflammatory signaling pathways has facilitated hopes of identifying a pharmacological target for neuroprotective therapies that counteract traumatic consequences in the CNS [31]. The gene discussed is LRRK2; the disease is Parkinson disease.